Immunochemicals: A Global Strategic Business Report
San Jose, California (PRWEB) April 27, 2012
Follow us on LinkedIn – The global immunochemicals market is an evolving and dynamic market, witnessing robust growth due to increase in demand from sectors such as counter bio-terrorism, healthcare and agriculture. Demand for immunochemicals is also set to rise against the backdrop of rise in research activity in the area of improving quality and nutrition of food, rise in production of pharmaceutical and industrial products, and increasing food production. Bio-terrorism is an emerging opportunity for immunochemicals, as efforts to develop effective tools for detection of hazardous toxins gain momentum. In the healthcare sector, increasing demand for cancer research is the major driving force for the global immunochemicals market. Catalogue antibody market is gaining momentum thanks to increasing supplier base along with rise in availability of a wide selection of antibodies. However, the scenario is changing with the advent of proteomics and identification of newer targets, which in turn is fostering the demand for custom antibodies.
Significant opportunities are emerging for custom antibodies in the areas of proteome research and genome projects, which enable discovery of novel proteins. Consequently, this provides the need for manufacturers to increase their stocks of antibodies. Although the prices of custom antibodies are much higher than catalogue antibodies, demand for the former continues to grow unabated. This trend can be attributed to the fact that researchers exhibit higher inclination towards these antibodies. With the researchers possessing adequate funds at their disposal, manufacturers have an incentive to retain higher prices of these antibodies. The pattern and pace of progress in the research antibodies market is linked to developments in the field of therapeutic antibodies sector. However, the high risk associated with the therapeutic business implies that several new entrants regard research antibody market as a potential gateway for future entry into the therapeutic antibody segment. The US and UK are among the major consumers of research antibodies, primarily due to the fact that these countries are home to a large number R&D units active in the antibodies domain.
The immunochemicals market is highly fragmented and intensely competitive, and involves the participation of more than 300 companies operating in the market. Companies operating in the research immunochemistry market are different from those operating in the therapeutic immunochemistry segment. The high cost associated with addressing concerns pertaining to FDA clinical compliance implies that therapeutic immunochemistry companies require greater financial support, when compared to firms engaged in the development of research antibodies. The immunochemicals market is expected to witness substantial consolidation and restructuring activity in the future. The presence of a large number of players is forcing companies to sustain operations by focusing on self-production of new antibodies. Intense competition is also leading to competitive pricing, which in turn constricts revenue generation. Moreover, the high price commanded by research antibodies, although lower in comparison to the price of therapeutic antibodies, is also a major driving factor for the foray of new entrants, including academicians, to the sector.
The US represents the largest regional market for immunochemicals worldwide, as stated by the new market research report on Immunochemicals. However, growth in the global immunochemicals market is projected to be driven by the Chinese market. China is projected to post a compounded annual growth rate of 15.5% during the analysis period 2009-2017. Immunochemicals market in the country, and other major Asian markets such as Australia and India is a relatively small. However, the growing emphasis on biotechnology sector is contributing to the increased demand for research antibodies in these countries. Demand for immunochemicals in Asia is on rise due to substantial support from governments in countries such as India and China together with their emergence as major centers of clinical research worldwide. Catalog Antibodies represents the largest market segment for immunochemicals. However, custom antibodies are projected to spearhead growth in the global market.
Major players profiled in the report include Abbott Diagnostics, Advanced ImmunoChemical, Beckman Coulter, Inc., BIOTREND Chemikalien GmbH, Dako, Life Technologies Corporation, Millipore Corporation, MorphoSys AG, Roche Group, and Rockland Immunochemicals among others.
The research report titled “Immunochemicals: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides comprehensive market overview, trends & issues, segment market analysis, recent industry activity and profiles of market players worldwide. Analysis and overview is provided for the years 2009 through 2017, for major geographic markets, including the US, Canada, Japan, Europe, China and Rest of World. Segments analyzed include Catalog Antibodies and Custom Antibodies. The study also provides historic data for the period 2003 through 2008.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/